Dabigatran Etexilate Capsules, 75 mg, 60-count (6x10)blister pack recall — FDA D-0738-2026
Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability